tri-GalNAc-COOH

• CAT Number: I036287
• CAS Number: 1953146-81-0
• Molecular Formula: C75H134N10O35
• Molecular Weight: 1735.91
• Purity: ≥95%
• Synonyms: 3-[2-[2-[2-[2-[3-[[1,3-bis[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]-2-[[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]methyl]propan-2-yl]amino]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid
• InChI: InChI=1S/C75H134N10O35/c1-49(89)82-63-69(104)66(101)52(43-86)118-72(63)115-27-7-4-13-55(92)76-21-10-24-79-58(95)16-31-112-46-75(85-61(98)19-30-107-35-37-109-39-41-111-42-40-110-38-36-108-34-20-62(99)100,47-113-32-17-59(96)80-25-11-22-77-56(93)14-5-8-28-116-73-64(83-50(2)90)70(105)67(102)53(44-87)119-73)48-114-33-18-60(97)81-26-12-23-78-57(94)15-6-9-29-117-74-65(84-51(3)91)71(106)68(103)54(45-88)120-74/h52-54,63-74,86-88,101-106H,4-48H2,1-3H3,(H,76,92)(H,77,93)(H,78,94)(H,79,95)(H,80,96)(H,81,97)(H,82,89)(H,83,90)(H,84,91)(H,85,98)(H,99,100)/t52-,53-,54-,63-,64-,65-,66+,67+,68+,69-,70-,71-,72-,73-,74-/m1/s1
• InChIKey: SPYOMGAJOYWUJU-JNYSMVCCSA-N
• SMILES: CC(=O)N[C@@H]1[C@H]([C@H]([C@H](O[C@H]1OCCCCC(=O)NCCCNC(=O)CCOCC(COCCC(=O)NCCCNC(=O)CCCCO[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O)NC(=O)C)(COCCC(=O)NCCCNC(=O)CCCCO[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)CO)O)O)NC(=O)C)NC(=O)CCOCCOCCOCCOCCOCCC(=O)O)CO)O)O

tri-GalNAc-COOH（Cat No.:I036287）is a trivalent N-acetylgalactosamine (GalNAc) ligand functionalized with a carboxylic acid group, designed for targeted delivery to hepatocytes via the asialoglycoprotein receptor (ASGPR). This highly specific interaction enhances liver targeting, making tri-GalNAc-COOH a valuable moiety in the development of liver-directed therapeutics, including siRNA, antisense oligonucleotides, and small molecules. Its trivalent GalNAc structure ensures high binding affinity and efficient cellular uptake. The carboxylic acid group allows for easy conjugation to therapeutic payloads, facilitating drug design aimed at improving pharmacokinetics, efficacy, and safety in liver-specific disease treatments.